Drug, bio-affecting and body treating compositions inventions 02/08

20080051315 - Grp receptor-related methods for the treating and preventing fear-related disorders: This invention provides a method for treating a subject afflicted with a fear-related disorder comprising administering to the subject a therapeutically effective amount of a gastrin-releasing peptide receptor agonist. This invention further provides a method for inhibiting in a subject the onset of a fear-related disorder resulting from exposure to... Agent: Cooper & Dunham, LLP

20080051319 - Inhibiting jnk signaling promotes cns axon regeneration: Regeneration of a lesioned CNS axon of mature neuron, determined to be subject to regeneration inhibition by endogenous cJun-N-terminal kinase (JNK), is promoted by contacting the neuron with an exogenous JNK inhibitor at a concentration sufficient to partially inhibit the JNK, and thereby promote a resultant regeneration of the axon.... Agent: Richard Aron Osman

20080051323 - Chloroquine drug compositions and methods for their synthesis: The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include... Agent: Kenneth M. Kosak

20080051325 - Oligopeptide: The object of the present invention is to provide an oligopeptide having hair growth promoting activity. The present invention provides an oligopeptide which is represented by the formula (I): X1-X2-X3-X4-X5-X6-X7, or the like wherein X1 represents an amino acid residue such as Ser, X2 represents an amino acid residue such... Agent: Morrison & Foerster LLP

20080051327 - Crystals of an aurora-a tpx2 complex, tpx2 binding site of aurora-a, aurora-a ligands and their use: The present invention relates to crystals of phosphorylated Aurora-A kinase fragment alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands, in particular allosteric inhibitors of Aurora-A, that bind to the Aurora-A kinase and their... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080051329 - Fsh and fsh variant formulations, products and methods: This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080051330 - Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses: Novel compositions and methods of treating and preventing a viral infection are provided. A method of blocking a viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which involves administering to a subject suffering or about to suffer from a viral infection a therapeutically effective amount of a... Agent: Don D. Cha

20080051332 - Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone: A method for modulating hematopoietic stem cells and treating a hematologic disease in a mammal comprising administering intranasally a therapeutically effective amount of a PTH formulation. The PTH formulation may contain teriparatide.... Agent: Nastech Pharmaceutical Company Inc

20080051350 - Therapeutic use for a group of sulphated polysaccharides: The present invention relates to the use of a sulphated polysaccharide in acid form or as a physiologically acceptable salt thereof, selected from the group consisting of inulin sulphate, gellan sulphate, pullulan sulphate, curdlan sulphate, alginiq acid sulphate, laminarin sulphate, and pectin sulphate, for the preparation of a medicament for... Agent: Venable LLP

20080051352 - Novel process for the preparation of telithromycin: e

20080051354 - Human schwannoma cell line: In a preferred embodiment, the present invention relates to a Schwannoma cell line derived from a Schwann tumor in a patient with Neurofibromatosis type 2 (NF2) and immortalized with HPV E6-E7 genes. The cell line has a unique splice site mutation of the NF2 gene. The immortalized cell line is... Agent: Knobbe Martens Olson & Bear LLP

20080051355 - System for obfuscating identity: Compositions, apparatus, systems, kits, and methods for obfuscating the nucleic acid and/or protein content of an environment.... Agent: Searete LLC Clarence T. Tegreene

20080051364 - Therapeutic treatment of accelerated bone resorption: m

20080051365 - Treatment of inflammation: The present invention concerns the therapeutic treatment of inflammatory conditions by a combined administration of methotrexate and an agonist of the A3 adenosine receptor. Provided are methods of therapeutic treatment comprising such a combined administration, pharmaceutical compositions useful in such methods comprising either an and use if either an agonist... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080051367 - Hyaluronan used in improvement of anti-oxidation and proliferation in chondrocytes: The present invention relates to the use of hyaluronan in protecting chondrocytes against oxidative damages and further promoting their proliferation. Particularly, the present invention relates to the use of hyaluronan with a molecular weight of 600,000-1,200,000 Dalton in protecting chondrocytes against reactive oxygen damages and further promoting their proliferation.... Agent: Troxell Law Office PLLC

20080051316 - Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment: Methods of treating a mammal at risk for ischemia-reperfusion injury are provided. The methods comprise administering an adrenomedullin binding protein-1 (AMBP-1) to the mammal in sufficient amount to reduce the injury. Also provided are methods of treating a mammal at risk for ischemia-reperfusion injury to the bowel. The methods comprise... Agent: Amster, Rothstein & Ebenstein LLP

20080051318 - Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods... Agent: Celera, An Applera Business Unit

20080051317 - Polypeptides comprising unnatural amino acids, methods for their production and uses therefor: Certain aspects of the present invention provide artificial polypeptides containing one or more unnatural amino acids and methods for producing and using the artificial polypeptides.... Agent: Wolf Greenfield & Sacks, P.C.

20080051320 - S-nitrosoprotein preparation and production method therefor: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The... Agent: Kubovcik & Kubovcik

20080051321 - Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity: Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Alk1, Alk2, Ar1, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the... Agent: Patrick H. Higgins Mathews, Collins, Shepherd & Mckay

20080051322 - 14400, 2838, 14618, 15334, 14274, 32164, 39404, 38911, 26904, 31237, 18057, 16405, 32705, 23224, 27423, 32700, 32712 and 12216, novel seven-transmembrane proteins/g-protein coupled receptors: The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further... Agent: Millennium Pharmaceuticals, Inc.

20080051324 - Medium-chain length fatty alcohols as stimulators of hematopoiesis: Medium-chain length fatty alcohols such as octanol, decanol, dodecanol, or analogues thereof can be used as a stimulator of hematopoiesis, hematopoietic stem cell proliferation, and/or proliferation of one or more of the progenitors of red or white blood cells (e.g., erythrocyte, leukocyte, neutrophil, granulocyte, megakaryocyte, or any combination thereof). It... Agent: Nixon & Vanderhye, PC

20080051326 - Antiinfective lipopeptides: The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080051338 - 98 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080051334 - Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases: The present invention provides a novel protein encoded by the KCNC1 gene and discloses the differential expression of the gene KCNC1 coding for KCNC1 proteins in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a... Agent: Venable LLP

20080051333 - Human alpha-defensins inhibit interleukin-1beta release: Human α-defensins are inhibitors of interleukin-1β post transitional processing and release. Interleukin-1β is a key cytokine involved in the initiation and amplification of the inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1(HNP-1) produced mainly by neutrophils, and human α-defensin 5(HD-5)... Agent: Aaron T. Olejniczak Andrus, Sceales, Starke & Sawall, LLP

20080051341 - Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome: A substance including the chemical structures of bicyclo[3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo[3.2.1]octan alone or in... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080051343 - Method for fostering bone formation and preservation: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any... Agent: Ostrolenk Faber Gerb & Soffen

20080051337 - Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease: The methodologies of the present invention demonstrate that a critical balance between pro- and anti-amyloidogenic molecules exists that regulates amyloid formation and cell death in Alzheimer's disease and Parkinson's disease. β-Synuclein, the non-amyloidogenic homologue of α-synuclein, is a negative modulator of α-synuclein and Aβ aggregation, having neuroprotective properties against α-synuclein... Agent: Morrison & Foerster LLP

20080051335 - Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers: Methods and compositions for the sustained release of treatment agents to treat an occluded blood vessel and affected tissue and/or organs are disclosed. Porous or non-porous bioabsorbable glass, metal or ceramic bead, rod or fiber particles can be loaded with a treatment agent, and optionally an image-enhancing agent, and coated... Agent: Blakely Sokoloff Taylor & Zafman

20080051339 - Modulators of pharmacological agents: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves,... Agent: King & Spalding LLP

20080051328 - Novel muscle growth regulator: A muscle growth regulating factor includes polynucleotide and polypeptide sequences, promoter sequences, constructs comprising the sequences, and compositions for regulating muscle growth and treating diseases associated with muscle growth. The present sequences can be used in identifying animals with altered muscle mass, and for selective breeding programs to produce animals... Agent: Knobbe Martens Olson & Bear LLP

20080051345 - Pharmaceutical compositions comprising fragments and homologs of troponin subunits: The present invention relates to pharmaceutical compositions comprising therapeutically effective amounts of troponin C, I or T subunits, fragments or homologs for the treatment of diseases or disorders involving abnormal angiogenesis and methods of use thereof.... Agent: David S. Resnick

20080051336 - Relaxin-3 chimeric polypeptides and their preparation and use: Chimeric polypeptides of relaxin-3, prepropolypeptides thereof, polynucleotides encoding such polypeptides, and associated expression vectors and host cells are described. The polypeptides may be used to prepare receptor-ligand complexes with GPCR135 or GPCR142, which may be used in assay methods.... Agent: Philip S. Johnson Johnson & Johnson

20080051342 - Trps1-mediated modulation of hair growth: The present invention provides for methods of inhibiting hair growth, comprising decreasing the level of TRPS1 mRNA and/or protein in hair follicle cells of a subject. The present invention also provides for methods of promoting hair growth, comprising increasing the level of TRPS1 mRNA and/or protein in hair follicle cells... Agent: Baker Botts L.L.P.

20080051340 - Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods: Members of the TGF-β superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics.... Agent: Wyeth/finnegan Henderson, LLP

20080051344 - Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof: The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation... Agent: Sughrue Mion, PLLC

20080051346 - Compounds and methods for modulating cell-adhesion mediated drug resistance: e

20080051347 - Tumour-associated peptides binding to mhc-molecules: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080051349 - Peptide antagonists of zonulin and methods for use of the same: Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions.... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20080051348 - Treatment of infections and other disorders: A method of treatment for treating, inhibiting, reducing or at least partly preventing respiratory or pulmonary microbial infection or gastrointestinal disorder of tissue of a subject, includes administering to a subject an effective amount of a composition including a polypeptide including thymosin β4 (TB4), an isoform of TB4, an N-terminal... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080051351 - Substances, compositions, and methods for treating alopecia: Substances, compositions and methods for hair treatment based on ultra-low molecular weight hyaluronic acid oligomers, possibly combined with trichogenic substances, useful for preventing hair loss and favouring its regrowth in subjects affected by androgenetic alopecia, alopecia areata, alopecia mucinosa and related disorders.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080051353 - Avermectin and avermectin monosaccharide substituted in the 4\"- and 4\" position respectively: A compound of the formula (I) wherein the bond between carbon atoms 22 and 23 indicated with a broken line is a single or double bond, m is 0 or 1, R1 represents a C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl group, R2 represents a hydrocarbyl group or a substituted hydrocarbyl group, and... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080051359 - Antisense oligonucleotide modulation of stat3 expression: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and... Agent: Eli Lilly & Company

20080051362 - Antisense therapy for hormone-regulated tumors: A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an... Agent: Marina Larson & Associates, LLC

20080051357 - Composition for attenuating neuropathic pain comprising a recombinant ventor expressing gad65: Provided is a pharmaceutical composition for attenuation of neuropathic pain comprising a GAD65-expressing recombinant vector. Direct introduction of the pharmaceutical composition of the present invention into a sciatic nerve leads to immediate therapeutic effects on peripheral neuropathic pain with a sustained and constant duration for several months. Therefore, the composition... Agent: Squire, Sanders & Dempsey L.l.p

20080051363 - G-rich polynucleotides as a novel therapeutic for the treatment of huntington's disease: The present invention relates to oligonucleotide compositions and therapeutic uses thereof to modify protein-protein interactions. In particular, the invention relates to the use of a guanidine-rich oligonucleotides to disrupt disease-causing protein aggregates, for example, Huntington's Disease (HD) protein aggregates... Agent: Mccarter & English, LLP Basil S. Krikelis

20080051358 - Novel human lysosomal protein and methods of its use: The gene associated and causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2, has been identified and characterized. The translation product of this gene is a novel protease and a deficiency in this activity results in LINCL. Identification of CLN2 will not only aid in the prevention of LINCL... Agent: Klauber & Jackson

20080051360 - Pkc ligands and polynucleotides encoding pkc ligands: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate PKC activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope... Agent: Sughrue Mion, PLLC

20080051361 - Rnai-mediated inhibition of gremlin for treatment of iop-related conditions: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.... Agent: Alcon

20080051356 - Truncated 24kda basic fibroblast growth factor: The invention relates to fragments of an amino acid sequence of mature, full length 24 kDa fibroblast growth factor-2 or an analog thereof. The fragments have an activity that inhibits the migration of cultured cells as well as inhibiting angiogenesis, tumor growth, or any other processes that involve the migration... Agent: T. D. Foster

20080051366 - Aminosugar, glycosaminoglycan, and s-adenoslymethionine composition for the treatment and repair of connective tissue: A composition for the protection, treatment and repair and for reducing the inflammation of connective tissue in mammals and a method for the treatment of connective tissue in mammals by the administration of the composition. The composition includes S-Adenosylmethionine (SAM), and a component selected from an aminosugar or salts thereof... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080051368 - Process for the isolation and stabilization of low-molecular weight aminoglycans form waste egg shells: wherein M may be at one or more instances Na, Ca, K, Mg: and n is an integer between 20 and 40: (a) pre-preparation of the waste egg-shells for extraction of the embryonic low molecular weight aminoglycan compound of formula I using a polar organic solvent in water; (b) extraction... Agent: Bomi Patel-framroze

20080051369 - Skin cosmetic material: e

20080051370 - Ruthenium complexes for treating cancers: The invention concerns uses or methods for treating proliferative pathologies, in particular cancers, using ruthenium compounds and compositions containing the same. The invention also concerns novel ruthenium compounds, as well as their preparation method.... Agent: Nixon & Vanderhye, PC

20080051371 - Creatine phosphate analog prodrugs, compositions and uses thereof: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080051372 - Methods utilizing cell-signaling lysophospholipids: The invention relates to methods of modulating neurite outgrowth, in culture or in a subject. The methods generally utilize cell-signaling phospholipids which interact and bind to the G protein-coupled cellular receptors (GPCRs). Such phospholipids include lysophospholipids, as well as synthetic lysophospholipid receptor agonists and antagonists that may be chemically distinct... Agent: Michael Best & Friedrich LLP

20080051373 - Parenteral preparations of gi-safer phospholipid-associated anti-inflammatories and methods of preparation and use: Parenteral preparations of phospholipid-associated anti-inflammatories (PL-AIs) are described to treat pain/inflammation, with reduced gastrointestinal (GI) toxicity. The PL-AIs can be composed of phosphatidylcholine (“PC”) associated with non-steroidal anti-inflammatory drugs (“NSAIDs”). To prepare the PL-AIs, a phospholipid is mixed with an NSAID in a polar solvent, solvent is removed, suspended in... Agent: Jackson Walker LLP

20080051374 - Therapeutic amides and related compounds: r

20080051375 - Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a vitamin D compound in combination with at least one additional therapeutic agent, such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising vitamin D compounds and at least... Agent: Jones Day

20080051376 - Method for producing albumin-corticoid conjugates: The invention relates to corticoid/transport protein conjugates, methods for the production thereof, and the use of the same in medicine, especially for the treatment of tumours and inflammatory processes, and for immunosuppression.... Agent: Morris Manning Martin LLP

20080051377 - Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080051378 - Combinations comprising antimuscarinic agents and corticosteroids: e

20080051379 - Compositions and methods for the treatment of peripheral b-cell neoplasms: The present invention is directed to the use of a PDE4 inhibitor and a glucocorticoid to treat peripheral B-cell neoplasms. In particular, the present invention provides a method of treating individuals (e.g. patients) diagnosed with peripheral B-cell leukemias by administering pharmaceutical compositions comprising Type 4 cyclic adenosine monophosphate phosphodiesterase inhibitors... Agent: Ronald I. Eisenstein

20080051380 - Methods and compositions for treating cancer: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a... Agent: Jones Day

20080051381 - Suppression of estrus in mares by a single injection method: The present invention generally relates to methods of suppressing estrus in breeding or competitive animals comprising parenterally administering to breeding animals an estrus suppressing amount of 17-α-Allyl-17-β-hydroxyoestra-4,9,11-trien-3-one. According to the method of the present invention, estrus can be suppressed for any of a variety of periods including 30 days or... Agent: Roetzel & Andress

20080051382 - Crystalline forms of 3-beta-amino 17-methylene androstane-6-alpha 7-beta-diol hydrochloride: The invention relates to novel crystalline forms of 3-beta-amino-17-methylene-androstane-6-alpha,7-beta-diol hydrochloride, referred to as form A, form B and form C, a method for preparing same, the use thereof as a drug, and pharmaceutical compositions containing same.... Agent: Seed Intellectual Property Law Group PLLC

20080051383 - Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed... Agent: Myers Bigel Sibley & Sajovec

20080051384 - Antiviral agents: Disclosed are compounds and compositions of Formula (I) and their uses for treating Flaviviridae family virus infections.... Agent: Foley & Lardner LLP

20080051385 - Ocular allergy treatments: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.... Agent: Philip S. Johnson Johnson & Johnson

20080051387 - Tetrahydropyrido[3,4-d]pyrimidines and related analogues: in which variables are as described herein, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are partially useful in the treatment of a variety of disorders in humans, domesticated companion... Agent: Edward Angell Palmer & Dodge, LLP Client: Neurogen Corporation

20080051386 - Tricyclic pyrazole derivatives as cannabinoid receptor modulators:

20080051388 - Novel compounds that inhibit factor xa activity:

20080051389 - Small molecule apoptosis promoters: The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and... Agent: Morrison & Foerster LLP

20080051391 - Fungicidal agent combinations: e

20080051390 - Imidazole amines as inhibitors of beta-secretase: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.... Agent: Wyeth Patent Law Group

20080051392 - Pharmaceutical combinations for the treatment of respiratory diseases: e

20080051394 - 6h-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands: in which R1, R2, R3 and R4 are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease,... Agent: Millen, White, Zelano & Branigan, P.C.

20080051393 - Novel cannabinoids and methods of use: Water- and lipid-soluble cannabinoid compounds that are agonists for CB1 and CB2 receptors are provided. The cannabinoid compounds are useful for the treatment of retinal neurodegenerative disorders such as glaucoma, diabetic retinopathy and macular degeneration.... Agent: Wilmerhale/dc

20080051395 - 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors: The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080051396 - Costunolide derivatives: e

20080051397 - Benzothiazole formulations and use thereof: The present invention is related to macrogol glyceride pharmaceutical formulations containing benzothiazole derivatives. In particular, the invention is related to benzothiazole stearoyl macrogol pharmaceutical formulations, method of preparation and use thereof.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080051398 - Method of treating brain cancer: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080051399 - Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors: s

20080051400 - Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound: The present invention relates to methods useful for treating or preventing anemia or thrombocytopenia, comprising administrating an effective amount of a Triheterocyclic Compound to a subject in need thereof. The present invention also relates to methods useful for preventing anemia or thrombocytopenia in a subject, comprising administrating an effective amount... Agent: Wilson Sonsini Goodrich & Rosati

20080051401 - 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer: The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in... Agent: Morgan Lewis & Bockius LLP

20080051402 - Method of inhibiting c-kit kinase: e

20080051403 - Treatment for alzheimer's disease and related conditions: This invention provides the combination of a growth hormone secretagogue and a p38 kinase inhibitor for use in treatment or prevention of a disease associated with deposition of Aβ in the brain.... Agent: Merck And Co., Inc

20080051404 - Heteroaryl compounds useful as inhibitors of e1 activating enzymes: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.... Agent: Millennium Pharmaceuticals, Inc.

20080051405 - Therapeutic agents: The present invention provides compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, type II diabetes, Metabolic syndrome and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease,... Agent: Pepper Hamilton LLP

20080051406 - Brimonidine and timolol compositions: Disclosed herein are compositions containing brimonidine and timolol. Therapeutic methods and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20080051407 - Antitumoral analogs of et-743: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene... Agent: Fish & Richardson PC

20080051408 - Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders: The invention relates to the use of PDE5 inhibitors, preferably sildenafil or tadalafil, optionally in combination with a further active ingredient, for treating and/or preventing hypopigmentary disorders.... Agent: Pearl Cohen Zedek Latzer, LLP

20080051409 - Indolizine carboxamides and aza and diaza derivatives thereof: e

20080051410 - Protein kinase targeted therapeutics: The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream... Agent: Casimir Jones, S.c.

20080051411 - Salts of fenofibric acid and pharmaceutical formulations thereof: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In... Agent: Robert Deberardine Abbott Laboratories

20080051412 - Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses: The present invention provides stereoisomers and stereoisomeric mixtures of 3-aminocarbonyl-bicycloheptene-2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080051413 - Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance: The effects of KMUP-3, (7-[2-[4-(4-Nitrobezene)peperazinyl]ethyl]-1,3-dimethylxanthine) on tracheal smooth muscle are provided. Intratracheal instillation of KMUP-3 avoids bronchoconstriction, decreases of lung resistance, and increases of dynamic lung compliance. These merits provide insightful benefits for the treatment in asthma and COPD (chronic obstructive pulmonary disease).... Agent: Trojan Law Offices

20080051414 - Protein kinase inhibitors: e

20080051415 - Novel piperazines, pharmaceutical compositions and methods of use thereof: Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080051416 - Novel compounds: s

20080051417 - Uses of selective cyclooxygenase-1 inhibitors: The present invention discloses effect of non-selective COX1 inhibitor such as aspirin, statins, thiazolidinediones or combinations thereof on COX2. Also disclosed herein is a method to avoid the adverse effects that the non-selective COX1 inhibitor may have when administered with statins and/or thiazolidinediones.... Agent: Benjamin Aaron Adler Adler & Associates

20080051418 - Arylalkanoic acid derivative: e

20080051419 - Amine derivatives useful as anticancer agents: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, D, E, V, W, Y, R1, R2, R5, R6, L, and u are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient... Agent: Pfizer Inc

20080051420 - New compounds 317: d

20080051421 - Pyrazolo-pyridine: wherein A, D, E, L, M, Q, R1, R2 and R3 are as defined hereinabove. The present invention also relates to a process for their preparation, a pharmaceutical composition containing said derivatives and a method of treating or preventing acute or chronic neurological disorder comprising administering to a patient in... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080051422 - 4-aminoquinazoline derivatives and methods of use thereof: This invention relates to novel 4-aminoquinazolines, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and... Agent: Edwards Angell Palmer & Dodge LLP

20080051423 - Nitrogen heterocycle biaryls for osteoporosis and other diseases: i

20080051424 - Heterocyclyl-substituted nonadepsipeptides: The invention relates to nonadepsipeptides and methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.... Agent: Morrison & Foerster LLP

20080051425 - Vinorelbine derivatives: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20080051426 - Indoloquinoline compounds as calcium channel blockers: Various calcium channel blockers and pharmaceutical compositions containing these compounds are disclosed. Calcium channel blockers are compounds capable of inhibiting calcium ion channels. Methods for preparing calcium channel blockers and their use as calcium channel antagonists are also disclosed.... Agent: Manfred E. Wolff

20080051427 - Pharmaceutical compositions and methods of using same: A pharmaceutical composition is provided that comprises a solid dispersion of implitapide. Such solid dispersions may include implitapide and least one pharmaceutically acceptable excipient. In some embodiments, the disclosed solid dispersions comprise substantially amorphous implitapide.... Agent: Goodwin Procter LLP Patent Administrator

20080051428 - Pyrroloquinoline quinone drugs and methods of use thereof: The invention includes compositions comprising substantially purified pyrroloquinoline quinone, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a composition of the invention with a human... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080051429 - Use of 4-amino-piperidines for treating sleep disorders: Inverse agonists and antagonists of serotonin receptors are disclosed for use in treating sleep disorders such as insomnia, and specifically sleep maintenance insomnia. The compound increase slow wave sleep, decrease the number of awakenings after sleep onset, and decrease the time awake after sleep onset.... Agent: Knobbe Martens Olson & Bear LLP

20080051430 - Acylated piperidine derivatives as melanocortin 4-receptor agonists: Certain novel N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction,... Agent: Merck And Co., Inc

20080051431 - Methods and compositions using immunomodulatory compounds in combination therapy: Provided herein are compositions comprising one or more immunomodulatory compounds and valproic acid, hydroxyurea or trichostatin A, methods for their use in CD34+ hematopoietic stem cell expansion in vitro and in vivo for bone marrow reconstitution and bone marrow transplantation, increasing fetal hemoglobin expression, and methods for treating, preventing and/or... Agent: Jones Day

20080051432 - Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors: wherein n represents 1, 2, 3, 4, 5 or 6; R1 represents from one to four of the same or different substituents selected from F, Cl, Br, C1-4 alkyl, OH, OC1-4 alkyl, NO2, NHC(O)C1-4 alkyl, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2; R2 represents OR3, NR3R4, N(R3)COR4, O2CR5; R3 and R4 represent... Agent: Matthias Scholl

20080051433 - Pyrrole-3-carboxamide derivatives for the treatment of obesity: The present invention relates to compounds of Formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20080051435 - Crystalline and amorphous forms of tiagabine: The present invention provides 24 new forms of tiagabine, including 22 new crystalline forms of tiagabine and its salts, an amorphous form of tiagabine free base, and a cocrystal form of tiagabine hydrochloride with 2-furancarboxylic acid. The present invention further provides a process for preparing each of the new tiagabine... Agent: Cephalon, Inc.

20080051434 - Hemiasterlin derivatives and uses thereof in the treatment of cancer: e

20080051436 - Use of acylaminothiazole derivatives as therapeutic agents: Wherein R1, R2, R′2, R3, R4 and R5 are as described herein. Specifically, the compounds of the present invention exhibit an inhibitory effect on the production of β-amyloid peptide (β-A4) by inhibition of gamma protease. Therefore, the compounds of the present invention are useful in the treatment of pathologies such... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080051437 - Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation: The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.... Agent: Heller Ehrman LLP

20080051438 - Preventive/therapeutic compositions useful for treating cardiovascular diseases: The present invention provides compositions that exert a superior hypotensive action while inhibiting an increase in heart rate. The present invention provides antihypertensives and preventive/therapeutic compositions useful in the treatment of cardiovascular diseases, which contain cilnidipine and at least one angiotensin II receptor blocker(s). The present invention also provides methods... Agent: Cermak & Kenealy LLP Acs LLC

20080051440 - Compositions for weight management: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows am efficient treatment regime thereof are... Agent: Martin D. Moynihan Prtsi, Inc.

20080051439 - Methods of food intake management: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The... Agent: Martin D. Moynihan Prtsi, Inc.

20080051442 - Agent for prevention and treatment of cancer comprising oxadiazole urea compound obstructing activity of stat: Disclosed herein is an agent for preventing and treating cancer comprising an oxadiazole urea compound represented by Chemical Formula 1, below, as an effective ingredient. The oxadiazole urea compound effectively inhibits the growth of cancer cell lines and the activity of STAT3, and may be thus useful in the prevention... Agent: Lucas & Mercanti, LLP

20080051441 - Aryl sulphonamide modulators: s

20080051443 - Compounds for the reduction of excessive food intake: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080051444 - Compounds for the reduction of excessive food intake: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080051445 - 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-acp reductase of type ii fatty acid synthesis pathway and other cell growth pathways: The current invention presents enoyl-ACP reductase, an enzyme of the type II fatty acid synthesis pathway as a target for treating human malarias and other infectious diseases. We also present in the current invention, 2-thioxothiazolidin-4-ones as antimicrobial and antimalarial agents. We provide 2-thioxothiazolidin-4-ones as antimicrobial and antimalarial agents either alone... Agent: Ladas & Parry

20080051446 - Heterocyclocarboxamide derivatives: The invention relates to a fungicidally active compound of formula (I): where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, provided that the ring is not 1,2,3-triazole, the ring being substituted by groups R8, R9 and R10;... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080051448 - Stabilized extended release pharmaceutical compositions comprising an amg-coa reductase inhibitor: The present invention is a new stable extended release drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a matrix-forming agent, and a method for manufacturing same. When applied to acid-labile drugs... Agent: Peacock Myers, P.C.

20080051447 - Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phospholipase-a2 inhibitors: The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in... Agent: Ilypsa-mcandrews C/o Mcandrews, Held & Madison Street

20080051449 - Preparation of atorvastatin calcium form vi and compositions thereof: The present invention provides processes to prepare atorvastatin calcium Form VI, pharmaceutical compositions comprising atorvastatin calcium Form VI, and processes to prepare said compositions. An aspect of the invention relates to atorvastatin calcium Form VI compositions having enhanced bioavailability when administered orally to humans.... Agent: Dr. Reddy's Laboratories, Inc.

20080051450 - Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions: This invention describes a process for the production of ANHYDROUS active pharmaceutical ingredients (APIs); a process for the preparation of HYDRATED active pharmaceutical ingredients, a process for the preparation of sterile and stable injectable solutions, and their use, more specifically, APIs which are taxane derivatives, especially (2R,3S) 4-acetoxy-2-α-benzoyloxy-5β-20-epoxy-1,7-β-10-β-tri-hydroxy-9-oxo-tax-11-en-13α-il 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I);... Agent: Birch Stewart Kolasch & Birch

20080051451 - Autoimmune conditions and nadph oxidase defects: The invention relates to methods and materials involved in treating autoimmune conditions. In particular, the invention relates to methods and compounds (and compositions including the compounds) involved in treating, preventing, or delaying the onset of autoimmune conditions. The compounds include one or more isoprenoid units. The compounds can enhance NADPH... Agent: Fish & Richardson PC

20080051453 - Sorbic acid analog co-crystals: The present invention relates to a pharmaceutical co-crystal comprising an active pharmaceutical ingredient and a co-crystal agent having the structure R1—C(═O)XH.... Agent: Amgen Inc.

20080051452 - Hexanoic acid derivatives as dipeptidyl peptidase inhibitors: The present invention is directed to novel hexanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080051454 - Compositions and methods for transient receptor potential vanilloid (trpv) channel mediated treatments: The present inventions relate to therapeutic compositions comprising, and methods utilizing, arachidonic acid derivatives and analogs for treatment of patients demonstrating symptoms of pathological conditions. Specifically, the inventions relate to therapeutic compositions for activating transient receptor potential vanilloid-1 channels (TRPV1). Additionally, therapeutic compositions are provided for increasing TRPV1-type responses. These... Agent: Medlen & Carroll, LLP

20080051455 - Method of treating an animal's exterior for cleaning and/or insect repellency: A method of treating animals to reduce the presence of annoying insects around the animal, help clean the animal's exterior, add luster and sheen to the animal's coat or hide, and provide stain repellency includes the application of a gelled composition to the exterior of an animal. The composition includes... Agent: Clark & Brody

20080051456 - Glycine reuptake inhibitors for treatment of drug dependence: The invention relates to a method of treatment or prevention of drug addiction, in particular alcoholism, in humans, comprising administering to a subject, in need thereof, an effective amount of a Gly-T1 inhibitor, in particular N-methyl-N-[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-phenyl-2-naphthalenyl]methyl glycine or a pharmaceutically acceptable salt thereof.... Agent: Organon Usa, Inc. Patent Department

20080051458 - Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use: Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of α-amino acids suitable for oral administration using sustained... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080051457 - Optically active phthalamide derivative, agricultural or horticultural insecticide, and method of using the same: (wherein each of R1 and R2 represents H, optionally substituted C1-C6 alkyl, or C1-C6 alkoxycarbonyl; R3 represents C1-C6 alkyl; A represents H, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, optionally substituted phenoxy C1-C6 alkyl, or the like; p represents 0, 1, 2, 3, or 4; q represents 0, 1, or 2;... Agent: Manelli Denison & Selter

20080051459 - Long term 24-hour intestinal administration of levodopa/carbidopa: A method of treating Parkinson's Disease comprising intestinally administering to a patient in need thereof a pharmaceutically effective amount of a composition comprising levodopa and optionally carbidopa continuously over a period of greater than 16 hours.... Agent: Mayer Brown LLP

20080051461 - Peeling process based on surfactants and acids: Process for the treatment of human skin, by applying topically onto the skin a composition containing in a physiologically acceptable medium (i) at least one hydroxy acid selected from the α-hydroxy acids, β-hydroxy acids, α-keto acids, β-keto acids and mixtures thereof, and (ii) at least 5% by weight, relative to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080051460 - Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 μg per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080051462 - Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors: The invention relates generally to methods of treating cell proliferative diseases with HSP90 inhibitors and, depending on the specific aspect and embodiment(s) claimed, to the treatment of proliferative diseases that are associated with fusion proteins, e.g., berab1, or mutant proteins or cellular protein isoforms, e.g., mutant forms of p53.... Agent: Biogen Idec / Finnegan Henderson, LLP

20080051463 - Anthracene compounds and their use for treating benign and malignant tumor disorders: The present invention provides novel anthracene compounds according to the formulae (I) and (II) and also selected anthracene compound compounds. The present invention furthermore provides a process for preparing such anthracene compounds. Also provided are pharmaceutical formulations comprising these anthracene compounds. The anthracene compounds provided are particularly suitable for the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080051464 - Protein phosphatase inhibitors: A method of inhibiting protein tyrosine phosphatase in a subject includes administering to the subject a therapeutically effective amount of at least one benzo-1,4-quinone, phenyl isothiazolone, or analog thereof to the subject.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20080051465 - Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080051466 - Isoalpha acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on isoalpha acids, commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080051467 - Linear and branched alcohol ethoxylates for controlling insects: Compounds for controlling aquatic breeding insects including an ethoxylated alcohol with a carbon chain length of about 10 to about 24 carbon atoms and about 0 to about 16 moles of ethylene oxide per mole of alcohol, where the carbon chain is linear or branched with an alkyl group are... Agent: Cognis Corporation Patent Department

20080051468 - Dual phase cosmetic composition: The present invention relates to a liquid dual phase cosmetic or pharmaceutical composition comprising an oil phase and an aqueous phase, the composition containing as a demixing agent a film forming agent such as polyvinylpyrrolidone and derivatives thereof. The compositions of the invention are particularly useful as makeup removers.... Agent: The Estee Lauder Cos, Inc

20080051469 - Dual phase cosmetic composition: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface... Agent: Foley And Lardner LLP Suite 500

20080051470 - Sensory wax for cosmetic and/or pharmaceutical formulations: A fatty acid ester of pentaerythritol, a pentaerythritol oligomer, or mixtures thereof, where the fatty acid has 6 to 22 carbon atoms, and the ester contains less than 0.3% by weight C17 fatty acid acyl groups and has a melting point of at least 30° C. is provided. A process... Agent: Cognis Corporation Patent Department

20080045448 - Reversing autonomic nervous system dysfunction by potentiating methylation: The present invention is a method and composition for reversing dysfunction of the human autonomic nervous system. The invention consists of administering a methylation-promoting composition that promotes uninterrupted recycling of homocysteine to methionine and uninterrupted processing and removal of metabolic products of stress.... Agent: Intellectual Property Strategists, LLC

20080045449 - Novel lipid mixtures for synthetic surfactants: The present invention provides novel lipid mixtures for synthetic surfactants. In particular, the invention provides a specific lipid mixture containing a specific amount of polyunsaturated phospholipids to be used for the preparation of synthetic surfactants. Said surfactants and pharmaceutical compositions thereof are useful for the treatment of surfactant deficiencies like... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080045467 - Composition containing ginsenoside f1 or compound k for skin external application: The present invention relates to an inhibitor for the biosynthesis of gelatinase comprising ginsenoside F1 (20-O-β-D-glucopyranosyl-20(S)-protopanaxatriol) or compound K (20-0-β-D-glucopyranosyl-20(S)-protopanaxadiol), which is a chief metabolite of ginseng saponin, as an active ingredient; and a cosmetic/medical composition for the prevention of skin-aging comprising the same which is superior in inhibiting the... Agent: Sughrue Mion, PLLC

20080045475 - Elemental cellular therapy is a genetic, cellular and disease-modifying therapy which enhances the systemic conduct of genetic and cellular transmethylation activity resulting in enhancement of concerted genetic and cellular metabolic, physiologic and hom: e

20080045477 - Series of new 4,6-diamino-1,2-dihydro-1-aryl-1,3,5-triazines, substituted by an adamantyl moiety in the position 2 of triazine-their corresponding salts, isomers,steroisomers, enantiomers, free bases and the complexes of all the above with natural macromo: A series of new 4,6-diamino-1,2-dihydro-1-aryl-2-(-tricyclo[3.3.1.13,7]decyl]-1,3,5-triazines where the aryl group is a substituted or unsubstituted phenyl, or naphthyl-group, as pharmaceutically accepted salts or as free bases. The phenyl group substituents are halides, alkyls, alkoxyls or nitro group. One or more of the above substituents are found one or more times each... Agent: Watov & Kipnes, P.C.

20080045444 - Compositions and methods for treating cardiovascular disease and myocardial infarction with dipeptidyl peptidase inhibitors or b type natriuretic peptide analogues resistant to prolyl-specific dipeptidyl degradation: The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl.... Agent: Foley & Lardner LLP

20080045443 - Compositions for inhibiting plexin-a1-dap12 interactions and methods of treating inflammatory, autoimmune or bone resorption diseases using the same: Disclosed are compositions and methods of treating an inflammatory, autoimmune or bone resorption disease by inhibiting plexin-A1-DAP12 interaction, plexin-A1-Trem-2 interaction or DAP12-Trem-2 interaction.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080045445 - Modulating notch1 signaling pathway for treating neuroendocrine tumors: Methods and pharmaceutical compositions for treating or suppressing symptoms of neuroendocrine (NE) tumors comprising increasing the levels or activities of Notch1 protein or other components of the Notch1 signaling pathway of the cancer cells. Also disclosed are pharmaceutical compositions for the methods.... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20080045447 - Fibrilliform-free insulin composition: Compositions and methods are disclosed for treating a patient with insulin, wherein a composition in a form suitable for nasal delivery to a patient comprises a therapeutically effective amount of insulin, a permeation enhancer, a liquid carrier, and an acid present in said composition in an amount sufficient to provide... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080045446 - Insulin composition: Pharmaceutical compositions for nasal administration to humans, or to warm-blooded animals, comprise: (A) a therapeutically effective amount of insulin; (B) a permeation enhancer; and (C) a liquid carrier; the compositions being further comprised of, or characterized by, any, or each, of: (D) a combination of non-ionic surfactants; wherein the combination... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080045457 - Ancestral hepatitis c virus envelope protein sequence: The present invention provides ancestral sequences for hepatitis C virus (HCV) envelope proteins, as well as uses for such sequences in inducing protective immune responses in subjects infected or at risk of infection with HCV.... Agent: Saint Louis University Office Of Innovation And Intellectual Property

20080045450 - Glp-2 derivatives: Analogs of GLP-2, pharmaceutical compositions comprising GLP-2 analogs, and methods of treating diseases and disorders comprising administering such analogs or compositions are provided.... Agent: Novo Nordisk, Inc. Patent Department

20080045453 - Method of producing biologically active vitamin k dependent proteins by recombinant methods: The invention relates to commercially viable methods for producing biologically active vitamin K dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic... Agent: Knobbe Martens Olson & Bear LLP

20080045451 - Novel thymidylate synthase mutants: Novel thymidylate synthase (TS mutants) are disclosed differing from human wild type thymidylate synthase in single, double, or multiple mutations, which show intact enzyme activity and enhanced resistance to TS-inhibiting drugs like 5-fluorouracil or 5-fluoro-2-deoxyuridinemonophosphate. All these mutants can be used for the protection of normal human cell populations against... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080045458 - Paralytic peptide for use in neuromuscular therapy: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.... Agent: Synnestvedt & Lechner, LLP

20080045454 - Polynucleotide encoding a trim-cyp polypeptide, compositions thereof, and methods of using same: The invention provides an isolated nucleic acid encoding a TRIM—cyclophilin A fusion sequence encoding a TRIMcyp fusion protein which is active as an anti-viral agent, and in particular an anti-HIV-1 agent. The invention provides for a nucleic acid encoding a polypeptide having both TRIM activity and cyclophilin activity. The invention... Agent: Wilmerhale/columbia University

20080045455 - Rage fusion proteins, formulations, and methods of use thereof: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20080045452 - Regulation of cytokine synthesis and release: Methods of treatment and prevention of diseases associated with release of neutrophil elastase and IL-8 by administration of TFPI and analogs of TFPI are disclosed. Methods of determining efficacy of treatment with TFPI, patient's responsiveness to treatment with TFPI, and the ultimate determination of patient prognosis are also disclosed.... Agent: Novartis Vaccines And Diagnostics Inc.

20080045456 - Treatment of disease: The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene... Agent: Wolf Greenfield & Sacks, P.C.

20080045459 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20080045461 - N-terminally modified glp-1 receptor modulators: The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that may... Agent: Louis J. Wille Bristol-myers Squibb Company

20080045460 - Treatment of prostate cancer by inhibiting lyn-tyrosine kinase: The present invention concerns methods for the treatment of prostate cancer by the inhibition of Lyn-kinase associated signal transduction. Preferred in accordance with the invention are inhibitors which comprise sequences derived from specific regions of the Lyn-kinase.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080045462 - Use of pentagastrin to inhibit gastric acid secretion or as a diuretic: This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.... Agent: Beyer Weaver LLP

20080045463 - Methods for lowering hif-1 mediated gene expression: The present invention relates to the elucidation of specific molecular features of endogenous amino acids and their derivatives for inhibiting hypoxia-inducible gene expression by preventing inactivation of hypoxia-inducible factor hydroxylating enzymes. This invention encompasses agents that can be used to reduce tissue vascularization, cancer cell survival, and to treat obesity.... Agent: Morgan Lewis & Bockius LLP

20080045464 - Natural sweetener: The invention relates to extracts, in particular non-nutrient phytochemicals, form sugar cane or sugar beet waste products, such as molasses, sugar mud and bagasse, which have Glycemic Index (GI) lowering properties and their use as sweeteners and in foods containing sugar.... Agent: Ip Group Of Dla Piper US LLP

20080045465 - Phosphole derivatives complexed with metals, and pharmaceutical uses thereof: The invention concerns pharmaceutical compositions comprising as active compound at least one compound of general formula (A), wherein: M represents a metal atom, and their uses in particular for preventing or treating pathologies associated with an excess activity of glutathion reductase and/or thioredoxin reductase.... Agent: Young & Thompson

20080045466 - Progression inhibitor for disease attributed to abnormal accumulation of liver fat: The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for... Agent: Sughrue Mion, PLLC

20080045468 - Antimicrobial 2-deoxystreptamine compounds: The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2″-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.... Agent: Seed Intellectual Property Law Group PLLC

20080045470 - Ceramides and apoptosis-signaling ligand: The invention provides the compounds of formula ( ): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, A, X, Y, a, b and n are as defined herein. Also disclosed are methods for making the compounds of formula (I) and their use in treating or preventing diseases associated... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080045469 - Compositions and methods for inhibiting angiogenesis: Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is one of the most frequently expressed angiogenic factors in tumors. Development of VEGF antagonists has become an important approach in cancer therapy. Here we describe a novel anti-VEGF strategy by preventing VEGF secretion in tumors cells. We utilize the fact that placenta... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080045473 - Compositions and methods for oligonucleotide formulations: The present invention relates generally to immunostimulatory nucleic acids, compositions thereof and methods of using the immunostimulatory nucleic acids. In particular the invention relates to palindrome-containing immunostimulatory nucleic acids and the use of these nucleic acids in treating disease.... Agent: Wolf Greenfield & Sacks, P.C.

20080045474 - Method for treatment of invasive cells: A method for treating metastatic tumor cells of a subject is disclosed. The method comprises administrating to the subject an antisense molecule comprising a nucleotide sequence which is complementary to an RNA sequence of a protease activated receptor (PAR) protein, or an antibody molecule capable of binding to a PAR... Agent: Oliff & Berridge, PLC

20080045471 - Nucleic acids for apoptosis of cancer cells: The disclosure relates to nucleic acids having Apoptotic Sequence Nos. 5, 8, 9, 11, 14, 60 and 66. It also relates to agents targeting Apoptotic Sequences, said agents having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, and SEQ... Agent: Baker Botts L.L.P. Patent Department

20080045472 - Targets for human micro rnas in avian influenza virus (h5n1) genome: The present invention relates to targets for Human microRNAs in Avian Influenza Virus (H5N1) Genome and provides specific miRNA targets against H5N1 virus. Existing therapies for Avian flu are of limited use primarily due to genetic re-assortment of the viral genome, generating novel proteins, and thus escaping immune response. In... Agent: Seed Intellectual Property Law Group PLLC

20080045476 - Methods and compositions using sulodexide for the treatment of diabetic nephropathy: The present invention provides oral formulations of Sulodexide for the treatment of diabetic nephropathy in patients with both insulin dependent and non-insulin dependent diabetes mellitus. Oral formulations containing doses adapted for administration to obtain a reduction in albumin. excretion in patients with both micro and macro albuminuria and to produce... Agent: Jones Day

20080045478 - Flavonoid complexes: The invention relates to complexes of specific flavonoid derivatives, to preparations containing derivatives of this type, to corresponding methods for producing said derivatives or preparations containing the latter and to the use of the latter, in particular for the care, preservation or improvement of the general condition of the skin... Agent: Millen, White, Zelano & Branigan, P.C.

20080045479 - Compositions and methods for regulating mammalian keratinous tissue: Skin care co